Palisade Bio (NASDAQ:PALI) Downgraded to Sell Rating by Wall Street Zen

Palisade Bio (NASDAQ:PALI) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently weighed in on PALI. HC Wainwright started coverage on Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price for the company. Wolfe Research initiated coverage on Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.20.

Palisade Bio Trading Up 5.0%

PALI stock opened at $1.89 on Friday. The stock has a 50-day moving average price of $1.95 and a 200-day moving average price of $1.91. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.85. The firm has a market cap of $328.07 million, a PE ratio of -1.87 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts forecast that Palisade Bio will post -0.21 earnings per share for the current year.

Hedge Funds Weigh In On Palisade Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new stake in Palisade Bio in the 4th quarter valued at about $28,318,000. Commodore Capital LP acquired a new position in Palisade Bio during the 4th quarter worth approximately $26,896,000. Janus Henderson Group PLC bought a new position in Palisade Bio in the fourth quarter worth approximately $24,822,000. RA Capital Management L.P. bought a new position in Palisade Bio in the fourth quarter worth approximately $16,742,000. Finally, Eversept Partners LP acquired a new stake in Palisade Bio in the fourth quarter valued at approximately $12,670,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.